Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Imeglimin Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 80Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Poxel Reports Q2 And H1 2024 Revenue, Provides Corporate Update
    Poxel Reports Q2 And H1 2024 Revenue, Provides Corporate Update

    09 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240908901962/en

    BUSINESSWIRE
    09 Sep 2024
    Share Share
    Poxel Updates Q2 Financials Reschedules Annual General Meeting
    Poxel Updates Q2 Financials Reschedules Annual General Meeting

    15 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240714885795/en

    BUSINESSWIRE
    15 Jul 2024
    Share Share
    Poxel to Report Its 2023 Annual Results by the End of April 2024
    Poxel to Report Its 2023 Annual Results by the End of April 2024

    28 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240328548115/en

    BUSINESSWIRE
    28 Mar 2024
    Share Share
    Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA
    Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA

    03 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221002005044/en

    BUSINESSWIRE
    03 Oct 2022
    Share Share
    Poxel Reports Financial Results for First Half 2022 & Provides Corporate Update
    Poxel Reports Financial Results for First Half 2022 & Provides Corporate Update

    21 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220920006290/en

    BUSINESSWIRE
    21 Sep 2022
    Share Share
    IMEGLIMIN with Novell Process IMEGLIMIN
    IMEGLIMIN with Novell Process IMEGLIMIN

    22 Aug 2022

    // PRESS RELEASE

    https://virujgroup.com/imeglimin/

    PRESS RELEASE
    22 Aug 2022
    Share Share